Professor Philippe Clézardin

BSc, MSc, PhD, DSc

Department of Oncology and Metabolism

Honorary Professor of Bone Oncology

p.clezardin@sheffield.ac.uk

EU28, E Floor, The Medical School

Full contact details

Professor Philippe Clézardin
Department of Oncology and Metabolism
EU28, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - iicd-om-operational@sheffield.ac.uk

I was awarded my PhD from the University of Lyon, France, in 1984 after which I joined the Medical Research Council / Scottish National Blood Transfusion Centre in Edinburgh as a post-doctoral research associate for 2 years. I was appointed in 1987 as Research Scientist (Lecturer) at INSERM (National Institute for Health and Medical Research), Lyon, France. In 1990 I undertook a one-year sabbatical as visiting scientist at the Ottawa General Hospital (Ottawa, Canada). In 1991 I was appointed Senior Research Scientist (Senior Lecturer) and in 1993 Research Director 2nd class (Reader) at INSERM. In 2005 I was appointed Research Director 1st Class (Professor) and became head of the INSERM Research Unit UMR_S664 entitled: “Mechanisms and Treatments of Bone Metastases” (2005-2010) and then Director of the Federative Research Institute “IFR62” entitled: “Cancer, Nutrition and Metabolism” (14 laboratories, circa: 500 people; 2007-2010). From 2011, I am head of the INSERM Research Unit UMR_S1033 entitled: “Pathophysiology, Diagnosis and Treatments of Bone Diseases” (http://www.lyos.fr). I have recently joined the Department of Oncology & Metabolism at the University of Sheffield as a Professor of Bone Oncology.

Research interests

My main research interest is the understanding of molecular mechanisms that govern breast cancer cell colonisation of the bone marrow, with the goal of developing novel biomarkers to identify patients at high risk for developing bone metastasis.

Current projects:

ROBO. Role of axon guidance, roundabout (ROBO) transmembrane receptors in breast cancer bone metastasis formation.

LOXs. Role of lysyl oxidases in early onset of breast cancer bone metastasis formation.

AMG161. Anti-tumour effect of a human anti-RANKL monoclonal antibody on early-stage bone colonisation of human RANK-expressing breast cancer cells

MicroRNAs. Role of breast cancer stem cell-derived microRNAs, and their mRNA/protein targets in controlling bone metastasis formation.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, Ribelli G, Bonnelye E, Wikman H, Geraci S, Bonin F , Simonetti S et al (2021) Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene. View this article in WRRO
Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2020) Bone metastasis : mechanisms, therapies and biomarkers. Physiological Reviews. View this article in WRRO
Puppo M, Taipaleenmäki H, Hesse E & Clézardin P (2019) Non‐coding RNAs in bone remodelling and bone metastasis : mechanisms of action and translational relevance. British Journal of Pharmacology. View this article in WRRO
Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M , Mazel M et al (2019) ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene, 38(7), 950-964. View this article in WRRO
Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier C-H, Bachelier R, Allioli N, Hong S-S , Bartkowiak K et al (2018) miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes. Cancer Research, 78(18), 5259-5273. View this article in WRRO
Sousa S & Clézardin P (2018) Bone-targeted therapies in cancer-induced bone disease. Calcified Tissue International, 102(2), 227-250. View this article in WRRO
Reynaud C, Ferreras L, Di Mauro P, Kan C, Croset M, Bonnelye E, Pez F, Thomas C, Aimond G, Karnoub AE , Brevet M et al (2017) Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone. Cancer Research, 77(2), 268-278. View this article in WRRO
Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 27(3), 379-390.
Sahay D, Leblanc R, Grunewald TGP, Ambatipudi S, Ribeiro J, Clézardin P & Peyruchaud O (2015) The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget, 6(24), 20604-20620. View this article in WRRO
Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A & Clézardin P (2014) TWIST1Expression in Breast Cancer Cells Facilitates Bone Metastasis Formation. Journal of Bone and Mineral Research, 29(8), 1886-1899.
Benzaïd I, Mönkkönen H, Bonnelye E, Mönkkönen J & Clézardin P (2012) In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement. Clinical Cancer Research, 18(22), 6249-6259.
Coleman R, Gnant M, Morgan G & Clezardin P (2012) Effects of Bone-Targeted Agents on Cancer Progression and Mortality. JNCI Journal of the National Cancer Institute, 104(14), 1059-1067.
Fradet A, Sorel H, Bouazza L, Goehrig D, Dépalle B, Bellahcène A, Castronovo V, Follet H, Descotes F, Aubin JE , Clézardin P et al (2011) Dual Function of ERRα in Breast Cancer and Bone Metastasis Formation: Implication of VEGF and Osteoprotegerin. Cancer Research, 71(17), 5728-5738.
Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J, Touraine J-L & Clézardin P (2011) High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity In Vivo. Cancer Research, 71(13), 4562-4572.
Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J & Clézardin P (2007) A Cathepsin K Inhibitor Reduces Breast Cancer–Induced Osteolysis and Skeletal Tumor Burden. Cancer Research, 67(20), 9894-9902.
Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P & Clézardin P (2007) Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases. Cancer Research, 67(12), 5821-5830.

All publications

Journal articles

Massy E, Rousseau JC, Gueye M, Bonnelye E, Brevet M, Chambard L, Duruisseaux M, Borel O, Roger C, Guelminger R , Pialat JB et al (2021) Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma. Journal of Bone Oncology, 29, 100364-100364.
Puppo M, Valluru MK & Clézardin P (2021) MicroRNAs and their roles in breast cancer bone metastasis. Current Osteoporosis Reports.
Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, Ribelli G, Bonnelye E, Wikman H, Geraci S, Bonin F , Simonetti S et al (2021) Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene. View this article in WRRO
Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2020) Bone metastasis : mechanisms, therapies and biomarkers. Physiological Reviews. View this article in WRRO
Gardegaront M, Plet G, Delpuech B, Bouazza L, Brevet M, Pialat J-B, Clézardin P, Confavreux CB, Mitton D & Follet H (2020) Influence of human cancer cell lines on mechanical properties of mice tibia. Computer Methods in Biomechanics and Biomedical Engineering, 23(sup1), S115-S116.
Bouchet M, Lainé A, Boyault C, Proponnet-Guerault M, Meugnier E, Bouazza L, Kan CWS, Geraci S, El-Moghrabi S, Hernandez-Vargas H , Benetollo C et al (2020) ERRα expression in bone metastases leads to an exacerbated anti-tumor immune response. Cancer Research. View this article in WRRO
Das S, Clézardin P, Kamel S, Brazier M & Mentaverri R (2020) The CaSR in pathogenesis of breast cancer : a new target for early stage bone metastases. Frontiers in Oncology, 10(1). View this article in WRRO
Dewulf J, Vangestel C, Verhoeven Y, van Dam P, Elvas F, Van den Wyngaert T & Clézardin P (2019) Bone metastases in the era of targeted treatments : insights from molecular biology. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 63(2), 98-111. View this article in WRRO
Puppo M, Taipaleenmäki H, Hesse E & Clézardin P (2019) Non‐coding RNAs in bone remodelling and bone metastasis : mechanisms of action and translational relevance. British Journal of Pharmacology. View this article in WRRO
Peters S, Clézardin P, Márquez-Rodas I, Niepel D & Gedye C (2019) The RANK–RANKL axis : an opportunity for drug repurposing in cancer?. Clinical and Translational Oncology, 21(8), 977-991. View this article in WRRO
Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M , Mazel M et al (2019) ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene, 38(7), 950-964. View this article in WRRO
Delliaux C, Tian TV, Bouchet M, Fradet A, Vanpouille N, Flourens A, Deplus R, Villers A, Leroy X, Clézardin P , de Launoit Y et al (2018) TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. Cancer Letters, 438, 32-43.
Lelièvre L, Clézardin P, Magaud L, Roche L, Tubiana-Mathieu N, Tigaud J-D, Topart D, Raban N, Mouret-Reynier M-A & Mathevet P (2018) Comparative study of neoadjuvant chemotherapy with and without Zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: The NEOZOL study. Clinical Breast Cancer, 18(6), e1311-e1321. View this article in WRRO
Gineyts E, Bonnet N, Bertholon C, Millet M, Pagnon-Minot A, Borel O, Geraci S, Bonnelye E, Croset M, Suhail A , Truica C et al (2018) The C-terminal intact forms of periostin (iPTN) are surrogate markers for osteolytic lesions in experimental breast cancer bone metastasis. Calcified Tissue International, 103(5), 567-580. View this article in WRRO
Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier C-H, Bachelier R, Allioli N, Hong S-S , Bartkowiak K et al (2018) miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes. Cancer Research, 78(18), 5259-5273. View this article in WRRO
Kassem L, Clézardin P & Treilleux I (2018) RANK expression predicts long term outcome in early luminal breast cancer. Annals of Oncology, 29, vi31-vi31.
Chambard L, Girard N, Ollier E, Rousseau J-C, Duboeuf F, Carlier M-C, Brevet M, Szulc P, Pialat J-B, Wegrzyn J , Clezardin P et al (2018) Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. Bone, 108, 202-209.
Sousa S & Clézardin P (2018) Bone-targeted therapies in cancer-induced bone disease. Calcified Tissue International, 102(2), 227-250. View this article in WRRO
Clézardin P (2017) Pathophysiology of bone metastases from solid malignancies. Joint Bone Spine, 84(6), 677-684.
Delpuech B, Confavreux C, Bouazza L, Geraci S, Clezardin P, Mitton D & Follet H (2017) Effect of intra-tibial injection on mechanical properties of mouse bone. Computer Methods in Biomechanics and Biomedical Engineering, 20(sup1), S57-S58.
Boudot C, Hénaut L, Thiem U, Geraci S, Galante M, Saldanha P, Saidak Z, Six I, Clézardin P, Kamel S & Mentaverri R (2017) Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. Oncotarget, 8(34). View this article in WRRO
Fowlkes B, Ghanouni P, Sanghvi N, Coussios C, Lyon PC, Gray M, Mannaris C, Victor MDS, Stride E, Cleveland R , Carlisle R et al (2017) International Society for Therapeutic Ultrasound Conference 2016. Journal of Therapeutic Ultrasound, 5(S1).
Clézardin P (2017) Physiopathologie des métastases osseuses des tumeurs solides. Revue du Rhumatisme Monographies, 84(2), 107-114.
Reynaud C, Ferreras L, Di Mauro P, Kan C, Croset M, Bonnelye E, Pez F, Thomas C, Aimond G, Karnoub AE , Brevet M et al (2017) Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone. Cancer Research, 77(2), 268-278. View this article in WRRO
Fradet A, Bouchet M, Delliaux C, Gervais M, Kan C, Benetollo C, Pantano F, Vargas G, Bouazza L, Croset M , Bala Y et al (2016) Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. Oncotarget, 7(47), 77071-77086. View this article in WRRO
Kan C, Vargas G, Pape F & Clézardin P (2016) Cancer cell colonisation in the bone microenvironment. International Journal of Molecular Sciences, 17(10). View this article in WRRO
Le Pape F, Vargas G & Clézardin P (2016) The role of osteoclasts in breast cancer bone metastasis. Journal of Bone Oncology, 5(3), 93-95. View this article in WRRO
Pantano F, Croset M, Driouch K, Iuliani M, Fioramonti M, Santini D, Tonini G, Bednarz-Knoll N, Pantel K & Clézardin P (2016) Integrin a5 is an independent prognosis factor and a potential therapeutic target for breast cancer bone metastasis. Annals of Oncology, 27, iv60-iv60.
Lafond M, Mestas J-L, Prieur F, Chettab K, Geraci S, Clézardin P & Lafon C (2016) Unseeded Inertial Cavitation for Enhancing the Delivery of Chemotherapies: A Safety Study. Ultrasound in Medicine & Biology, 42(1), 220-231.
Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 27(3), 379-390.
Tardoski S, Gineyts E, Ngo J, Kocot A, Clézardin P & Melodelima D (2015) Low-Intensity Ultrasound Promotes Clathrin-Dependent Endocytosis for Drug Penetration into Tumor Cells. Ultrasound in Medicine & Biology, 41(10), 2740-2754.
Clément-Demange L & Clézardin P (2015) Emerging therapies in bone metastasis. Current Opinion in Pharmacology, 22, 79-86.
Sahay D, Leblanc R, Grunewald TGP, Ambatipudi S, Ribeiro J, Clézardin P & Peyruchaud O (2015) The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget, 6(24), 20604-20620. View this article in WRRO
Clézardin P (2015) Physiopathologie des métastases osseuses. Oncologie, 17(3), 69-74.
Arkko S, Zlatev HP, Mönkkönen H, Räikkönen J, Benzaïd I, Clézardin P, Mönkkönen J & Määttä JA (2015) Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells. Cancer Letters, 357(1), 279-285.
Richert L, Keller L, Wagner Q, Bornert F, Gros C, Bahi S, Clauss F, Bacon W, Clézardin P, Benkirane-Jessel N & Fioretti F (2015) Nanoscale Stiffness Distribution in Bone Metastasis. World Journal of Nano Science and Engineering, 05(04), 219-228.
Croset M, Kan C & Clézardin P (2015) Tumour-derived miRNAs and bone metastasis. BoneKEy Reports, 4.
Tardoski S, Ngo J, Gineyts E, Roux J-P, Clézardin P & Melodelima D (2015) Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer. Scientific Reports, 5(1). View this article in WRRO
Terpos E, Confavreux CB & Clézardin P (2015) Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. BoneKEy Reports, 4.
Amoroso V, Petrelli F, Pedersini R, Simoncini EL, Clézardin P, Barni S & Berruti A (2015) Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?. Future Oncology, 11(21), 2853-2856.
Sahay D, Leblanc R, Ribeiro J, Clezardin P & Peyruchaud O (2014) 562 Lysophosphatidic acid-induced breast cancer metastasis depends on LPA1/ZEB1/miR-21-activation pathway. European Journal of Cancer, 50, 182-182.
Leblanc R, Lee S-C, David M, Bordet J-C, Norman DD, Patil R, Miller D, Sahay D, Ribeiro J, Clézardin P , Tigyi GJ et al (2014) Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. Blood, 124(20), 3141-3150.
Raphaël M, Lehen’kyi V, Vandenberghe M, Beck B, Khalimonchyk S, Vanden Abeele F, Farsetti L, Germain E, Bokhobza A, Mihalache A , Gosset P et al (2014) TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proceedings of the National Academy of Sciences, 111(37), E3870-E3879.
Bachelier R, Confavreux CB, Peyruchaud O, Croset M, Goehrig D, van der Pluijm G & Clézardin P (2014) Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. International Journal of Cancer, 135(6), 1319-1329.
Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A & Clézardin P (2014) TWIST1Expression in Breast Cancer Cells Facilitates Bone Metastasis Formation. Journal of Bone and Mineral Research, 29(8), 1886-1899.
David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Vales RL , Jurdic P et al (2014) Lysophosphatidic Acid Receptor Type 1 (LPA1) Plays a Functional Role in Osteoclast Differentiation and Bone Resorption Activity. Journal of Biological Chemistry, 289(10), 6551-6564.
Girard N, Confavreux CB, Pialat JB, Devouassoux M, Clézardin P, Isaac S, Thivolet-Béjui F, Bringuier PP & Brevet M (2014) POUMOS : étude prospective de faisabilité du diagnostic moléculaire sur biopsie de métastase osseuse synchrone de cancer bronchopulmonaire. Revue des Maladies Respiratoires, 31, A131-A131.
Confavreux CB, Girard N, Pialat J-B, Bringuier P-P, Devouassoux-Shisheboran M, Rousseau J-C, Isaac S, Thivolet-Bejui F, Clezardin P & Brevet M (2014) Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). BoneKEy Reports, 3.
Vieillard MH, Chiras J, Clézardin P, Ferrero J-M, Barrière J & Beuzeboc P (2013) Os, cible thérapeutique (RPC 2013). Oncologie, 15(12), 673-686.
Ricci E, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluije G, Cecchini M, Thalmann G, Clezardin P & Colombel M (2013) Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. The Prostate, 73(16), 1738-1746.
Clézardin P (2013) Pathophysiology of bone metastases and new molecular targets involved in bone remodelling. Bulletin du Cancer, 100(11), 1083-1091.
Santana-Codina N, Carretero R, Sanz-Pamplona R, Cabrera T, Guney E, Oliva B, Clezardin P, Olarte OE, Loza-Alvarez P, Méndez-Lucas A , Perales JC et al (2013) A Transcriptome-proteome Integrated Network Identifies Endoplasmic Reticulum thiol oxidoreductase (ERp57) as a Hub that Mediates Bone Metastasis. Molecular & Cellular Proteomics, 12(8), 2111-2125.
Stresing V, Baltziskueta E, Rubio N, Blanco J, Arriba MC, Valls J, Janier M, Clézardin P, Sanz-Pamplona R, Nieva C , Marro M et al (2013) Erratum: Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene, 32(6), 804-804.
Stresing V, Baltziskueta E, Rubio N, Blanco J, Arriba M, Valls J, Janier M, Clézardin P, Sanz-Pamplona R, Nieva C , Marro M et al (2013) Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene, 32(6), 724-735.
Clézardin P (2013) Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. BoneKEy Reports, 2.
Thiem U, Boudot C, Lopez I, Hénaut L, Clézardin P, Kamel S & Mentaverri R (2012) The role of the calcium sensing receptor in the migration of breast cancer cells. Bone, 51(6), S28-S29.
Kischel P, Bellahcene A, Deux B, Lamour V, Dobson R, De Pauw E, Clezardin P & Castronovo V (2012) Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Research, 32(12), 5211-5220.
Pantano F, Clézardin P & Santini D (2012) RANK/RANKL pathway in cancer: Biological activity beyond bone?. Journal of Bone Oncology, 1(3), 67-68.
Benzaïd I, Mönkkönen H, Bonnelye E, Mönkkönen J & Clézardin P (2012) In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement. Clinical Cancer Research, 18(22), 6249-6259.
Clezardin P (2012) Bioluminescence Imaging of Prenylation Inhibition-Letter. Clinical Cancer Research, 18(21), 6077-6077.
Thariat J, Leysalle A, Vignot S, Marcy P-Y, Lacout A, Bera G, Lagrange J-L, Clezardin P & Chiras J (2012) Traitement local ablatif de la maladie oligométastatique osseuse (hors chirurgie). Cancer/Radiothérapie, 16(5-6), 330-338.
Gnant M & Clézardin P (2012) Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature. Cancer Treatment Reviews, 38(5), 407-415.
Coleman R, Gnant M, Morgan G & Clezardin P (2012) Effects of Bone-Targeted Agents on Cancer Progression and Mortality. JNCI Journal of the National Cancer Institute, 104(14), 1059-1067.
Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, Mehlen P, Arrigo A-P, Clézardin P & Diaz-Latoud C (2012) Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. British Journal of Cancer, 107(1), 63-70.
Dumont B, Castronovo V, Peulen O, Blétard N, Clézardin P, Delvenne P, De Pauw EA, Turtoi A & Bellahcène A (2012) Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. Journal of Proteome Research, 11(4), 2247-2260.
DAVID M, RIBEIRO J, DESCOTES F, SERRE C-M, BARBIER M, MURONE M, CLÉZARDIN P & PEYRUCHAUD O (2012) Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. International Journal of Oncology, 40(4), 1133-1141. View this article in WRRO
Clezardin P (2012) Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies. Anti-Cancer Agents in Medicinal Chemistry, 12(2), 102-113.
Clézardin P (2012) Pourquoi certains cancers métastasent-ils préférentiellement à l’os ?. Oncologie, 14(1), 31-36.
Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P & Thalmann G (2012) Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. The Prostate, 72(7), 713-720.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – November-December 2011. IBMS BoneKEy, 8(11), 305-312.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – October 2011. IBMS BoneKEy, 8(10), 428-432.
Benzaïd I, Mönkkönen H & Clézardin P (2011) 1074 POSTER Effects of Zoledronic Acid and Denosumab on Human Vy9V62 T-cell-Mediated Cell Death of RANK-Expressing Breast Cancer Cells. European Journal of Cancer, 47, S117-S117.
Croset M, Bachelier R, Allioli N, Hong SS, Aqami R & Clezardin P (2011) 5007 ORAL The MicroRNAs-30 Family Interferes With the Formation of Breast Cancer Bone Metastases by Targeting Osteomimetic Genes. European Journal of Cancer, 47, S332-S332.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – September 2011. IBMS BoneKEy, 8(9), 390-396.
Fradet A, Sorel H, Bouazza L, Goehrig D, Dépalle B, Bellahcène A, Castronovo V, Follet H, Descotes F, Aubin JE , Clézardin P et al (2011) Dual Function of ERRα in Breast Cancer and Bone Metastasis Formation: Implication of VEGF and Osteoprotegerin. Cancer Research, 71(17), 5728-5738.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – August 2011. IBMS BoneKEy, 8(8), 352-361.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – July 2011. IBMS BoneKEy, 8(7), 305-312.
Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J, Touraine J-L & Clézardin P (2011) High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity In Vivo. Cancer Research, 71(13), 4562-4572.
Clézardin P (2011) The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications. Bulletin du Cancer, 98(7), 837-846.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – June 2011. IBMS BoneKEy, 8(6), 257-263.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – May 2011. IBMS BoneKEy, 8(5), 211-220.
Clézardin P (2011) Therapeutic targets for bone metastases in breast cancer. Breast Cancer Research, 13(2). View this article in WRRO
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – April 2011. IBMS BoneKEy, 8(4), 171-177.
Ricci E, Bourrelie E, Martin X, Dumontet C, Clezardin P, Thalmann G & Colombel M (2011) 838 TESTING AND PROGNOSTIC IMPLICATIONS OF PROSTATE CANCER STEM CELLS IN BONE MARROW. European Urology Supplements, 10(2), 265-265.
Clézardin P (2011) Can bisphosphonates really reduce the risk of recurrences in early breast cancer?. IBMS BoneKEy, 8(3), 159-164.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – March 2011. IBMS BoneKEy, 8(3), 128-134.
Contié S, Voorzanger-Rousselot N, Litvin J, Clézardin P & Garnero P (2011) Erratum to “Periostin as a circulating marker for breast cancer bone metastases” [Bone 47S2 (2010) S328–S329]. Bone, 48(3), 672-672.
Pez F, Dayan F, Durivault J, Kaniewski B, Aimond G, Le Provost GS, Deux B, Clézardin P, Sommer P, Pouysségur J & Reynaud C (2011) The HIF-1–Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth. Cancer Research, 71(5), 1647-1657.
Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) Clinical and basic research papers – February 2011. IBMS BoneKEy, 8(2), 65-73.
Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V & Clézardin P (2011) Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone, 48(2), 259-266.
Benzaid* I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J & Clézardin P (2011) Zoledronic acid induces IPP accumulation and release from human cancer cells, which activates Vγ9Vδ2 T cell-differentiation and migration in vitro and mediates Vγ9Vδ2 T cell-induced cancer cell death in vivo. Bone, 48(1), S46-S46.
David M, Leblanc R, Deux B, Serre CM, Ribeiro J, Clézardin P & Peyruchaud* O (2011) Interaction of autotaxin with breast cancer cell integrins might contribute to lysophosphatidic acid-mediated bone metastases. Bone, 48(1), S39-S40.
Croset* M, Goëhrig D, Bonnelye E, Ansieau S, Puisieux A & Clézardin P (2011) Twist 1 expression in an osteotropic breast cancer cell line promotes bone metastasis formation in mouse. Bone, 48(1), S47-S48.
Contié S, Voorzanger-Rousselot N, Litvin J, Clézardin P & Garnero P (2011) Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. International Journal of Cancer, 128(2), 352-360.
Clézardin P (2011) Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class. Bone, 48(1), 71-79.
Clézardin P, Benzaïd I & Croucher PI (2011) Bisphosphonates in preclinical bone oncology. Bone, 49(1), 66-70.
Contié S, Voorzanger-Rousselot N, Litvin J, Bonnet N, Ferrari S, Clézardin P & Garnero P (2010) Development of a New ELISA for Serum Periostin: Evaluation of Growth-Related Changes and Bisphosphonate Treatment in Mice. Calcified Tissue International, 87(4), 341-350.
Clézardin P (2010) Propriétés antitumorales du bisphosphonate zolédronate et implications thérapeutiques potentielles en clinique. Bulletin du Cancer, 97(8), 937-949.
Fournier PG, Stresing V, Ebetino FH & Clezardin P (2010) How Do Bisphosphonates Inhibit Bone Metastasis In Vivo. Neoplasia, 12(7), 571-578.
Benzaid I & Clézardin P (2010) Nitrogen-containing bisphosphonates and human γδ T cells. IBMS BoneKEy, 7(6), 208-217.
Pez F, Dayan F, Durivault J, Kaniewski B, Aimond G, Deux B, Clezardin P, Sommer P, Pouysségur J & Reynaud C (2010) 531 Synergy between HIF1a and LOX is critical for tumour progression. European Journal of Cancer Supplements, 8(5), 135-136.
Green J & Clézardin P (2010) The Molecular Basis of Bisphosphonate Activity: A Preclinical Perspective. Seminars in Oncology, 37, S3-S11.
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P , Holen I et al (2010) Metastasis and bone loss: Advancing treatment and prevention. Cancer Treatment Reviews, 36(8), 615-620. View this article in WRRO
Stresing V, Deux B, Benzaid I, Mathevet P, Ebetino H & Clézardin P (2010) Frequent Intermittent Low-dose Therapy Accentuates the Antitumour Activity of the Bisphosphonate Risedronate In Vivo. Bone, 46, S43-S43.
Gonin V, Bachelier R, Deux B, Contié S, Bonnelye E, Rabbitts P, Wu J & Clézardin P (2010) Involvement of the Slit2/Robo1 Pathway in Breast Cancer Bone Metastasis. Bone, 46, S37-S37.
Arkko S, Mönkkönen J, Auriola S, Dronda IR, Benzaid I, Stresing V, Clezardin P & Mönkkönen H (2010) Zoledronic acid induces IPP release from cancer cells which causes Vgamma9Vdelta2 T cell expansion in PBMCs. Bone, 46, S40-S41.
David M, Wannecq E, Jansen S, Deux B, Ribeiro J, Serre C-M, Grès S, Bendriss-Vermare N, Bollen M, Saulnier-Blache J-S , Clézardin P et al (2010) Expression of lyosophospholipase D/autotaxin by breast cancer cells controls bone metastasis formation by increasing osteoclast differentiation. Bone, 46, S41-S41.
Benzaid I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J & Clézardin P (2010) Zoledronate-Induced IPP/ApppI (Phosphoantigen) Accumulation in Human Breast Cancer Cells Correlates with Vγ9VΔ2 T Cell-Mediated Cancer Cell Death In Vitro and In Vivo. Bone, 46, S43-S43.
Clezardin P & Massaia M (2010) Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy. Current Pharmaceutical Design, 16(27), 3007-3014.
Clezardin P (2010) Editorial [ Hot-topic: Molecularly Targeted Therapies in Breast Cancer Bone Metastases (Executive Editor: Philippe Clezardin)]. Current Pharmaceutical Design, 16(11), 1260-1261.
Daubiné F, Cortial D, Ladam G, Atmani H, Haïkel Y, Voegel J-C, Clézardin P & Benkirane-Jessel N (2009) Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. Biomaterials, 30(31), 6367-6373.
Contié S, Voorzanger-Rousselot N, Litvin J, Bonnet N, Ferrari S, Conway SJ, Clézardin P & Garnero P (2009) Development of a new ELISA for serum periostin: Growth-related changes and effects of bisphosphonate in mice. Bone, 44, S270-S270.
Clézardin P (2009) Insights into the antitumor effects of bisphosphonates from preclinical models and potential clinical implications. IBMS BoneKEy, 6(6), 210-217.
Serre CM, Ribeiro J, Bonnelye E, Clézardin P & Peyruchaud O (2009) Effect of lysophosphatidic acid (LPA) on osteoclastogenesis. Bone, 44, S135-S135.
Voorzanger-Rousselot N, Goehrig D, Facon T, Clézardin P & Garnero P (2009) Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. British Journal of Haematology, 145(2), 264-266.
Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen AJ, Clezardin P & Peyruchaud O (2009) Bioactive Lipids Lysophosphatidic Acid and Sphingosine 1-Phosphate Mediate Breast Cancer Cell Biological Functions Through Distinct Mechanisms (vol 18, pg 173, 2009). ONCOLOGY RESEARCH, 18(7), 357-357.
Clézardin P (2009) Physiopathologie des métastases osseuses. Oncologie, 11(1), 10-15.
Clezardin P (2009) Integrins in Bone Metastasis Formation and Potential Therapeutic Implications. Current Cancer Drug Targets, 9(7), 801-806.
Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen AJ, Clézardin P & Peyruchaud O (2009) Bioactive Lipids Lysophosphatidic Acid and Sphingosine 1-Phosphate Mediate Breast Cancer Cell Biological Functions Through Distinct Mechanisms. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 18(4), 173-184.
Fournier PGJ, Daubiné F, Lundy MW, Rogers MJ, Ebetino FH & Clézardin P (2008) Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth InhibitionIn vivo. Cancer Research, 68(21), 8945-8953.
Kischel P, Guillonneau F, Dumont B, Bellahcène A, Stresing V, Clézardin P, Pauw EAD & Castronovo V (2008) Cell Membrane Proteomic Analysis Identifies Proteins Differentially Expressed in Osteotropic Human Breast Cancer Cells. Neoplasia, 10(9), 1014-IN11.
Le Gall C, Bonnelye E & Clézardin P (2008) Cathepsin K inhibitors as treatment of bone metastasis. Current Opinion in Supportive and Palliative Care, 2(3), 218-222.
Ottewell PD, Deux B, Monkkonen H, Cross S, Coleman RE, Clezardin P & Holen I (2008) Differential Effect of Doxorubicin and Zoledronic Acid on Intraosseous versus Extraosseous Breast Tumor Growth In vivo. Clinical Cancer Research, 14(14), 4658-4666.
Clézardin P (2008) Pathogénie des métastases osseuses. Revue du Rhumatisme, 75(4), 327-331.
Garcia T, Jackson A, Bachelier R, Clément-Lacroix P, Baron R, Clézardin P & Pujuguet P (2008) A convenient clinically relevant model of human breast cancer bone metastasis. Clinical & Experimental Metastasis, 25(1), 33-42.
Stresing V, Daubiné F, Benzaid I, Mönkkönen H & Clézardin P (2007) Bisphosphonates in cancer therapy. Cancer Letters, 257(1), 16-35.
Clézardin P (2007) Frequent low-dose bisphosphonate therapy. Bone, 41(5), 901-902.
Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P & Garnero P (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. British Journal of Cancer, 97(7), 964-970.
Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J & Clézardin P (2007) A Cathepsin K Inhibitor Reduces Breast Cancer–Induced Osteolysis and Skeletal Tumor Burden. Cancer Research, 67(20), 9894-9902.
Buijs JT, Henriquez NV, van Overveld PGM, van der Horst G, Que I, Schwaninger R, Rentsch C, ten Dijke P, Cleton-Jansen A-M, Driouch K , Lidereau R et al (2007) Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer. Cancer Research, 67(18), 8742-8751.
Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P & Clézardin P (2007) Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases. Cancer Research, 67(12), 5821-5830.
Body J-J, Coleman R, Clezardin P, Ripamonti C, Rizzoli R & Aapro M (2007) International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. European Journal of Cancer, 43(5), 852-858.
Baum O, Hlushchuk R, Forster A, Greiner R, Clézardin P, Zhao Y, Djonov V & Gruber G (2007) Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the β3 integrin subunit. International Journal of Oncology, 30(2), 325-332.
Daubine F, Le Gall C, Gasser J, Green J & Clezardin P (2007) Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone Metastasis. JNCI Journal of the National Cancer Institute, 99(4), 322-330.
Henriquez NV, van Overveld PGM, Que I, Buijs JT, Bachelier R, Kaijzel EL, Löwik CWGM, Clezardin P & van der Pluijm G (2007) Advances in optical imaging and novel model systems for cancer metastasis research. Clinical & Experimental Metastasis, 24(8), 699-705.
Clezardin P & Teti A (2007) Bone metastasis: pathogenesis and therapeutic implications. Clinical & Experimental Metastasis, 24(8), 599-608.
Bellahcène A, Bachelier R, Detry C, Lidereau R, Clézardin P & Castronovo V (2007) Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Research and Treatment, 101(2), 135-148.
Boucharaba A, Serre C-M, Guglielmi J, Bordet J-C, Clezardin P & Peyruchaud O (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proceedings of the National Academy of Sciences, 103(25), 9643-9648.
Bellahcene A, Bachelier , Detry C, Lidereau R, Clezardin P & Castronovo V (2006) Transcriptome analysis reveals an osteomimetic phenotype for human bone metastatic breast cancer cells. European Journal of Cancer Supplements, 4(2), 163-163.
Staquet M-J, Couble M-L, Roméas A, Connolly M, Magloire H, Hynes RO, Clezardin P, Bleicher F & Farges J-C (2006) Expression and localisation of αv integrins in human odontoblasts. Cell and Tissue Research, 323(3), 457-463.
Fontana A, Filleur S, Guglielmi J, Frappart L, Bruno-Bossio G, Boissier S, Cabon F & Clézardin P (2005) Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1in vivo. International Journal of Cancer, 116(5), 686-691.
Clézardin P, Ebetino FH & Fournier PGJ (2005) Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity: Figure 1.. Cancer Research, 65(12), 4971-4974.
Peyruchaud O, Boucharaba A, Saulnier-Blache J-S & Clézardin P (2005) Acide lysophosphatidique : un nouveau lien entre plaquettes sanguines et métastases osseuses. médecine/sciences, 21(4), 353-355.
Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A, Degeorges A, Serre CM, Bouvier R, Clézardin P & Cabon F (2005) Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.. Cancer Res, 65(1), 300-308.
CLEZARDIN P (2005) Anti-tumour activity of zoledronic acid. Cancer Treatment Reviews, 31, 1-8.
Boucharaba A, Serre C-M, Grès S, Saulnier-Blache JS, Bordet J-C, Guglielmi J, Clézardin P & Peyruchaud O (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. Journal of Clinical Investigation, 114(12), 1714-1725.
Peyruchaud O, Serre C-M, NicAmhlaoibh R, Sveigaard C & Clézardin P (2004) [Does tumor angiogenesis play a role in bone metastatic process?].. Rev Med Suisse Romande, 124(2), 83-84.
Peyruchaud O, Serre C-M, NicAmhlaoibh R, Fournier P & Clézardin P (2003) Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity. Journal of Biological Chemistry, 278(46), 45826-45832.
Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clézardin P & Cabon F (2003) SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.. Cancer Res, 63(14), 3919-3922.
Colombel M, Fournier P, Bouvier R, Cabon F & Clezardin P (2003) Androgens repress the expression of thrombospondin-1, an inhibitor of angiogenesis, in the rat prostate and in hormone-responsive human prostate cancer. European Urology Supplements, 2(1), 82-82.
Clezardin P, Fournier P, Boissier S & Peyruchaud O (2003) In Vitro and In Vivo Antitumor Effects of Bisphosphonates. Current Medicinal Chemistry, 10(2), 173-180.
Clézardin P (2003) Biphosphonates and bone metastases of solid tumors: Therapeutic significance beyond osteolytic activity. Progres en Urologie, 13(2 SUPPL. 1), 28-35.
Green JR & Clézardin P (2002) Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis. American Journal of Clinical Oncology, 25, S3-S9.
Cl[eacute]zardin P (2002) The antitumor potential of bisphosphonates. Seminars in Oncology, 29(6 Suppl 21), 33-42.
Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M & Clézardin P (2002) Bisphosphonates inhibit angiogenesis in Vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Research, 62(22), 6538-6544.
Clézardin P (2002) Activité anti-tumorale des bisphosphonates : mythe ou réalité ?. Revue du Rhumatisme, 69(10-11), 997-1001.
Pecheur I, Peyruchaud O, Serre C, Guglielmi J, Voland C, Bourre F, Margue C, Cohen‐Solal M, Buffet A, Kieffer N & CléZardin P (2002) Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone. The FASEB Journal, 16(10), 1266-1268.
Colombel M, Fournier P, Boissier S, Martin X & Clezardin P (2002) The bisphosphonate zoledronic acid inhibits angiogenesis in vitro and testosterone-stimulated vascular regrowth in the rat ventral prostate. European Urology Supplements, 1(1), 52-52.
Filleur S (2001) In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes & Development, 15(11), 1373-1382.
Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM & Clézardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.. Cancer Res, 60(11), 2949-2954.
Clézardin P (2000) [Bone hyperresorption in bone metastases].. Presse Med, 29(9), 487-491.
Clézardin P, Gligorov J & Delmas P (2000) Mécanismes d'action des bisphosphonates sur les cellules tumorales et perspectives d'utilisation dans le traitement de l'ostéolyse maligne. Revue du Rhumatisme, 67(1), 28-36.
Clézardin P, Gligorov J & Delmas P (2000) Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis.. Joint Bone Spine, 67(1), 22-29.
Merle B, Durussel L, Delmas PD & Cl�zardin P (1999) Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. Journal of Cellular Biochemistry, 75(3), 538-546.
Bah I, David MP, Konan PG, Clezardin P & Colombel M (1999) Modulation of prostatic angiogenesis. Oncologie, 1(7), 428-432.
Magnetto S, Boissier S, Delmas PD & Clezardin P (1999) Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. International Journal of Cancer, 83(2), 263-269.
Clézardin P, Bruno-Bossio G, Fontana A, Serre CM, Magnetto S & Frappart L (1999) [Thrombospondins, tumor angiogenesis and breast cancer].. Pathol Biol (Paris), 47(4), 368-374.
Magnetto S, Bruno-Bossio G, Voland C, Lecerf J, Lawler J, Delmas P, Silverstein R & Clezardin P (1998) CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1.. Cell Biochem Funct, 16(3), 211-221.
Clezardin P (1998) Recent insights into the role of integrins in cancer metastasis. Cellular and Molecular Life Sciences (CMLS), 54(6), 541-548.
Merle B, Malaval L, Lawler J, Delmas P & Clezardin P (1997) Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. Journal of Cellular Biochemistry, 67(1), 75-83.
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD & Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.. Cancer Res, 57(18), 3890-3894.
CLEZARDIN P, LAWLER J, AMIRAL J, QUENTIN G & DELMAS P (1997) Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1. Biochemical Journal, 321(3), 819-827.
Bertin N, Clezardin P, Kubiak R & Frappart L (1997) Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia.. Cancer Res, 57(3), 396-399.
Boissier S, Cuzin B, Delmas PD & Clezardin P (1995) Clodronate selectively inhibits the attachment of highly metastatic prostate carcinoma cells to bone extracellular matrix. Bone, 17(6), 599-599.
Serre CM, Boivin G, Clezardin P, Delmas PD & Frappart L (1995) Distribution of thrombospondin and integrin ?v in DCIS, invasive ductal and lobular human breast carcinomas. Virchows Archiv, 427(4).
Pechoux C, Clezardin P, Dante R, Serre CM, Clerget M, Bertin N, Lawler J, Delmas PD, Vauzelle JL & Frappart L (1994) Localization of thrombospondin, CD36 and CD51 during prenatal development of the human mammary gland. Differentiation, 57(2), 133-141.
Péchoux C, Clezardin P, Dante R, Serre CM, Clerget M, Bertin N, Lawler J, Delmas PD, Vauzelle JL & Frappart L (1994) Localization of thrombospondin, CD36 and CD51 during prenatal development of the human mammary gland. Differentiation, 57(2), 133-133.
Abbadia Z, Amiral J, Trzeciak M-C, Delmas PD & Clezardin P (1993) The growth-supportive effect of thrombospondin (TSP1) and the expression of TSP1 by human MG-63 osteoblastic cells are both inhibited by dexamethasone. FEBS Letters, 335(2), 161-166.
Clezardin P, Drouin J, Morel-Kopp MC, Hanss M, Kehrel B, Serre CM, Kaplan C & Delmas PD (1993) Role of Platelet Membrane Glycoproteins Ib/IX and Ilb/IIIa, and of Platelet a-Granule Proteins in Platelet Aggregation Induced by Human Osteosarcoma Cells. Cancer Research, 53(19), 4695-4700.
Abbadia Z, Clezardin P, Serre C-M, Amiral J & Delmas PD (1993) Thrombospondin (TSP1) mediates in vitro proliferation of human MG-63 osteoblastic cells induced by α-thrombin. FEBS Letters, 329(3), 341-346.
Clezardin P, Clerget M & Delmas PD (1993) Expression of Thrombospondin (TSP1) and Its Receptors (CD36 and CD51) in Normal, Hyperplastic, and Neoplastic Human Breast. Cancer Research, 53(6), 1421-1430.
Clézardin P & Delmas PD (1993) [Role of osteoclasts in the physiopathological mechanisms of malignant osteolysis].. Bull Cancer, 80(10 Suppl), 11-15.
Breton-Gorius J, Clezardin P, Guichard J, Debili N, Malaval L, Vainchenker W, Cramer EM & Delmas PD (1992) Localization of platelet osteonectin at the internal face of the alpha- granule membranes in platelets and megakaryocytes. Blood, 79(4), 936-941.
Breton-Gorius J, Clezardin P, Guichard J, Debili N, Malaval L, Vainchenker W, Cramer EM & Delmas PD (1992) Localization of platelet osteonectin at the internal face of the alpha- granule membranes in platelets and megakaryocytes. Blood, 79(4), 936-941.
Clezardin P, Serre CM, Trzeciak MC, Drouin J & Delmas PD (1991) Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction.. Cancer Res, 51(10), 2621-2627.
Vuillard L, Clezardin P & Miller A (1991) Models of human platelet thrombospondin in solution. A dynamic light-scattering study. Biochemical Journal, 275(1), 263-266.
CLEZARDIN P, JOUISHOMME H, CHAVASSIEUX P & MARIE PJ (1989) Thrombospondin is synthesized and secreted by human osteoblasts and osteosarcoma cells. A model to study the different effects of thrombospondin in cell adhesion. European Journal of Biochemistry, 181(3), 721-726.
McGregor JL, Catimel B, Parmentier S, Clezardin P, Dechavanne M & Leung LL (1989) Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation.. J Biol Chem, 264(1), 501-506.
CLEZARDIN P, MALAVAL L, EHRENSPERGER A-S, DELMAS PD, DECHAVANNE M & MCGREGOR JL (1988) Complex formation of human thrombospondin with osteonectin. European Journal of Biochemistry, 175(2), 275-284.
Clezardin P, Bourdillon M-C, Hunter NR & McGregor JL (1988) Cell attachment and fibrinogen binding properties of platelet and endothelial cell thrombospondin are not affected by structural differences in the 70 and 18 kDa protease-resistant domains. FEBS Letters, 228(2), 215-218.
Clezardin P (1987) Thrombospondin. Hämostaseologie, 07(06), 172-182.
Clezardin P, Hunter N, Lawler J, Dawes J & McGregor J (1987) Production, Characterization, and Use of Monoclonal Antibodies Directed Against Human Blood Platelet Thrombospondin: Immunologic Comparison with Human Endothelial and Fibroblast Thrombospondins. Seminars in Thrombosis and Hemostasis, 13(03), 261-275.
Dawes J, Clezardin P & Pratt D (1987) Thrombospondin in Milk, Other Breast Secretions, and Breast Tissue. Seminars in Thrombosis and Hemostasis, 13(03), 378-384.
CLEZARDIN P, HUNTER NR, LAWLER JW, PRATT DA, McGREGOR JL, PEPPER DS & DAWES J (1986) Structural and immunological comparison of human thrombospondins isolated from platelets and from culture supernatants of endothelial cells and fibroblasts. Evidence for a thrombospondin polymorphism. European Journal of Biochemistry, 159(3), 569-579.
Clezardin P, Hunter NR, MacGregor IR, MacGregor JL, Pepper DS & Dawes J (1986) Tandem purification of mouse IgM monoclonal atibodies produced in vitro using anion-exchange and gel fast protein liquid chromatography. Journal of Chromatography A, 358, 209-218.
Clezardin P, Bougro G & McGregor JL (1986) Tandem purification of IgM monoclonal antibodies from mouse ascites fluids by anion-exchange and gel fast protein liquid chromatography. Journal of Chromatography A, 354, 425-433.
Clezardin P, Hunter NR, McGregor JL, Pepper DS & Dawes J (1986) Structural and immunological differences between human platelet and endothelial thrombospondins. FEBS Letters, 196(1), 49-53.
CLEZARDIN P, McGREGOR JL, LYON M, CLEMETSON KJ & HUPPERT J (1986) Characterization of two murine monoclonal antibodies (P10, P12) directed against different determinants on human blood platelet thrombospondin. European Journal of Biochemistry, 154(1), 95-102.
Clezardin P, McGregor JL, Dechavanne M & Clemetson KJ (1985) Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. British Journal of Haematology, 60(2), 331-344.
McGregor JL, Clezardin P, Manach M & Dechavanne M (1985) Tandem separation of labelled human blood platelet membrane glycoproteins by anion-exchange and gel fast protein liquid chromatography. Journal of Chromatography A, 326, 179-190.
McGREGOR JL, CLEZARDIN P, JAMES E, McGREGOR L, DECHAVANNE M & CLEMETSON KJ (1985) Identification and characterization of fragments of major glycoproteins from platelet membrane after chymotrypsin treatment. European Journal of Biochemistry, 148(1), 97-106.
Clezardin P, McGregor JL, Manach M, Boukerche H & Dechevanne M (1985) One-step procedure for the rapid isolation of mouse monoclonal antibodies and their antigen binding fragments by fast protein liquid chromatography on a mono Q anion-exchange column. Journal of Chromatography A, 319, 67-77.
Clezardin P, McGregor JL, Manach M, Robert F, Dechavanne M & Clemetson KJ (1984) Isolation of thrombospondin released from thrombinstimulated human platelets by fast protein liquid chromatography on an anion-exchange mono-q column. Journal of Chromatography A, 296, 249-256.
Dawes J, Clemetson KJ, Gogstad GO, McGregor J, Clezardin P, Prowse CV & Pepper DS (1983) A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, β-thromboglobulin and platelet factor 4 in healthy volunteers. Thrombosis Research, 29(6), 569-581.
McGregor JL, Clemetson KJ, James E, Clezardin P, Dechavanne M & Lüscher EF (1982) Tryptic peptide map analysis of the major human blood platelet membrane glycoproteins separated by two-dimensional polyacrylamide gel electrophoresis. Biochimica et Biophysica Acta (BBA) - Biomembranes, 689(3), 513-522.
Puppo M, Jaafar M, Diaz J-J, Marcel V & Clézardin P () MiRNAs and snoRNAs in Bone Metastasis: Functional Roles and Clinical Potential. Cancers, 15(1), 242-242.
Bellanger A, Le DT, Vendrell J, Wierinckx A, Pongor LS, Solassol J, Lachuer J, Clezardin P, Győrffy B & Cohen PA () Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. Frontiers in Oncology, 11.
Donini CF, El Helou M, Wierinckx A, Győrffy B, Aires S, Escande A, Croze S, Clezardin P, Lachuer J, Diab-Assaf M , Ghayad SE et al () Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. Frontiers in Oncology, 10.
Clement-Demange L, Le PF, Eckel B, Geraci S, Diaz-Latoud C & Clezardin P () Roundabout receptors: new actors in bone metastatic niche formation. Bone Abstracts.
Pantano F, Croset M, Driouch K, Bonnelye E, Bednarz-Knoll N, Hong S-S, Iuliani M, Fioramonti M, Santini D, Tonini G , Pantel K et al () Integrin α5 is an independent prognosis factor and a potential therapeutic target for breast cancer bone metastasis. Bone Abstracts.
Confavreux CB, Chambard L, Ollier E, Brevet M, Duboeuf F, Rousseau J-C, Pialat J-B, Wegrzyn J, Tescaru A, Szulc P , Carlier M-C et al () Bone and metabolic parameters are associated with overall survival in patients with bone metastases from adenocarcinoma lung cancer: the POUMOS study. Bone Abstracts.
Reynaud C, Ferreras L, Brevet M & Clezardin P () Lysyl oxidase promotes survival and outgrowth of colon cancer cells in the bone marrow, enabling bone metastasis formation. Bone Abstracts.
David M, Sahay D, Mege F, Descotes F, Leblanc R, Ribeiro J, Clézardin P & Peyruchaud O () Identification of Heparin-Binding EGF-Like Growth Factor (HB-EGF) as a Biomarker for Lysophosphatidic Acid Receptor Type 1 (LPA1) Activation in Human Breast and Prostate Cancers. PLoS ONE, 9(5), e97771-e97771. View this article in WRRO
Fradet A, Sorel H, Depalle B, Serre CM, Farlay D, Turtoi A, Bellahcene A, Follet H, Castronovo V, Clézardin P & Bonnelye E () A New Murine Model of Osteoblastic/Osteolytic Lesions from Human Androgen-Resistant Prostate Cancer. PLoS ONE, 8(9), e75092-e75092. View this article in WRRO
Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G , La Verde N et al () Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. PLoS ONE, 6(4), e19234-e19234. View this article in WRRO
David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre C-M, Grès S, Bendriss-Vermare N, Bollen M , Saez S et al () Cancer Cell Expression of Autotaxin Controls Bone Metastasis Formation in Mouse through Lysophosphatidic Acid-Dependent Activation of Osteoclasts. PLoS ONE, 5(3), e9741-e9741. View this article in WRRO
Saltel F, Chabadel A, Zhao Y, Lafage-Proust M-H, Clézardin P, Jurdic P & Bonnelye E () Transmigration: A New Property of Mature Multinucleated Osteoclasts. Journal of Bone and Mineral Research, 21(12), 1913-1923.
Peyruchaud O, Winding B, Pécheur I, Serre C-M, Delmas P & Clézardin P () Early Detection of Bone Metastases in a Murine Model Using Fluorescent Human Breast Cancer Cells: Application to the Use of the Bisphosphonate Zoledronic Acid in the Treatment of Osteolytic Lesions. Journal of Bone and Mineral Research, 16(11), 2027-2034.
Voland C, Serre C-M, Delmas P & Clézardin P () Platelet-Osteosarcoma Cell Interaction is Mediated Through a Specific Fibrinogen-Binding Sequence Located Within the N-Terminal Domain of Thrombospondin 1. Journal of Bone and Mineral Research, 15(2), 361-368.
Clezardin P, Malaval L, Trzeciak M-C, Guichard J, Lecompte T, Morel M-C, Dechavanne M, Breton-Gorius J, Delmas PD & Kaplan C () Osteonectin is an α-granule component involved with thrombospondin in platelet aggregation. Journal of Bone and Mineral Research, 6(10), 1059-1070.
Hinz N, Baranowsky A, Horn M, Kriegs M, Sibbertsen F, Smit DJ, Clezardin P, Lange T, Schinke T & Jücker M () Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis. Cells, 10(2), 430-430.
Confavreux CB, Follet H, Mitton D, Pialat JB & Clézardin P () Fracture Risk Evaluation of Bone Metastases: A Burning Issue. Cancers, 13(22), 5711-5711.

Chapters

Puppo M, Valluru MK & Clézardin P (2022) MicroRNAs and bone metastasis, Bone Cancer (pp. 457-469). Elsevier
Delpuech B, Nicolle S, Confavreux CB, Bouazza L, Clezardin P, Mitton D & Follet H (2020) Failure Prediction of Tumoral Bone with Osteolytic Lesion in Mice, Advanced Structured Materials (pp. 17-34). Springer International Publishing
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020) Bone metastases Springer Science and Business Media LLC
Clézardin P, Sousa S, Croset M, Pantano F & Confavreux C (2020) Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors, Encyclopedia of Bone Biology (pp. 403-420). Elsevier
Bernard M, Di Mauro P, Reynaud C, Diaz-Latoud C & Clézardin P (2019) Bone Metastases; Basic Aspects, Encyclopedia of Endocrine Diseases (pp. 304-309). Elsevier
Croset M & Clézardin P (2015) MicroRNA-mediated regulation of bone metastasis formation: from primary tumors to skeleton, Bone Cancer (pp. 479-489). Elsevier
Clézardin P (2010) Early Bone Metastasis-Associated Molecular and Cellular Events, Bone Cancer (pp. 41-45). Elsevier
Ando K, Arslandemir C, Bell WC, Berdal A, Berthold D, Bhat BM, Bhat RA, Bhattacharyya S, Billiard J, Blanchard F , Bodine PVN et al (2010) List of Contributors, Bone Cancer (pp. xi-xv). Elsevier
BOUKERCHE H, McGREGOR JL, McGREGOR L, CLEZARDIN P, CLEMETSON KJ, DECHAVANNE M & BROCHIER J (1985) Characterization of a Monoclonal Antibody Directed Against a Platelet Alpha-Granule Glycoprotein, Protides of the Biological Fluids (pp. 821-824). Elsevier
CLEZARDIN P, McGREGOR JL, LYON M, SHAO HZ, BOUKERCHE H, CLEMETSON KJ, DECHAVANNE M & HUPPERT J (1985) Characterization of Monoclonal Antibodies Specific for a High Molecular Weight Glycoprotein Secreted from Activated Human Blood Platelets, Protides of the Biological Fluids (pp. 815-820). Elsevier
Clezardin P, McGregor JL, James E, Dechavanne M & Clemetson KJ (1984) IDENTIFICATION OF CYTOPLASMIC AND MEMBRANE PLATELET GLYCOPROTEINS USING A COMBINATION OF SDS - POLYACRYLAMIDE GEL ELECTROPHORESIS AND 125I-LABELLED LECTINS, Proceedings of the Second Symposium Lyon, France, June 27–30, 1983 (pp. 601-604). De Gruyter
Clezardin P, McGregor JL, James E, Dechavanne M & Clemetson KJ (1984) Identification of Cytoplasmic and Membrane Platelet Glycoproteins Using a Combination of SDS-Polyacrylamide Gel Electrophoresis and 1251-Labelled Lectins, Proceedings of the Second Symposium Lyon, France, June 27–30, 1983 (pp. 601-604). De Gruyter
Coleman RE & Clézardin P () Antitumour Effects of Bisphosphonates, Textbook of Bone Metastases (pp. 345-350). John Wiley & Sons, Ltd

Conference proceedings papers

Das S, Gabrion A, Six I, Boudot C, Kamel S, Clezardin P, Brazier M & Mentaverri R (2019) Abstract 2859: Targeting the calcium sensing receptor in breast cancer cells diminishes colonization and migratory response in a trabecular bone explant model, and reduces osteolytic lesions in vivo. Tumor Biology
Das S, Gabrion A, Six I, Boudot C, Kamel S, Clezardin P, Brazier M & Mentaverri R (2019) Abstract 2859: Targeting the calcium sensing receptor in breast cancer cells diminishes colonization and migratory response in a trabecular bone explant model, and reduces osteolytic lesions in vivo. Tumor Biology
Vargas G, Bouchet M, Kan C, Benetollo C, Croset M, Mazel M, Cayrefourcq L, Vacher S, Pantano F, Driouch K , Bieche I et al (2018) ERRa in primary breast tumours promotes tumour cell dissemination to bone by regulating RANK. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 72-72)
Croset M, Pantano F, Kan C, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier C, Bachelier R, Allioli N, Hong SS , Bartkowiak K et al (2018) Abstract 486: MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Molecular and Cellular Biology / Genetics
Sousa S, Gineyts E, Geraci S, Croset M & Clézardin P (2018) Abstract 29: RANK-RANKL signaling inhibition delays early breast cancer bone metastasis formation. Tumor Biology
Pantano F, Croset M, Driouch K, Iuliani M, Fioramonti M, Santini D, Tonini G, Bednarz-Knoll N, Pantel K & Clezardin P (2016) Integrin a5 is an independent prognosis factor and a potential therapeutic target for breast cancer bone metastasis. ANNALS OF ONCOLOGY, Vol. 27
Gineyts E, Bonnet N, Bertholon C, Pagnon-Minot A, Borel O, Hartmann D, Chapurlat RD, Ferrari S, Garnero P, Clezardin P & Rousseau J-C (2016) ELISA MEASUREMENT OF CIRCULATING PERIOSTIN IN ANIMAL MODELS OF BONE LOSS OR BONE FORMATION AND IDENTIFICATION OF CIRCULATING AND TISSUE-SPECIFIC ASSOCIATED FORMS OF PERIOSTIN. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S207-S207)
Mathevet P, Magaud L & Clézardin P (2016) Abstract P6-13-19: Adding zoledronic acid to neo-adjuvant chemotherapy may improve the efficiency of chemotherapy in locally advanced breast cancer: Results from the prospective randomized study NEOZOL. Poster Session Abstracts
Reynaud C, Ferreras L & Clezardin P (2014) THE HIF-1 TARGET LYSYL OXIDASE PROMOTES SURVIVAL AND OUTGROWTH OF COLON CANCER CELLS IN THE BONE MARROW ENABLING BONE METASTASIS FORMATION. ANTICANCER RESEARCH, Vol. 34(10) (pp 6134-6134)
Sahay D, Leblanc R, Ribeiro J, Clézardin P & Peyruchaud O (2014) Abstract 1448: Disseminated tumor cell formation promoted by lysophosphatidic acid (LPA) involves ZEB1/miR21-dependent activation pathway. Molecular and Cellular Biology
Bouchet M, Fradet A, Delliaux C, Bouazza L, Pantano F, Leroy X, Bellahcene A, Castonovo V, Clezardin PAR, Duterque-Coquillaud M & Bonnelye E (2014) ERRalpha, a pro-Bone metastatic factor : Implication in metastatic Niche and prostate Cancer Stem Cells phenotype.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S13-S13)
Clement-Demange L, Eckel B, Gonin V, Goehrig D, Diaz-Latoud C & Clezardin PAR (2014) Roundabout receptors mediate breast cancer bone metastasis formation and progression.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S65-S66)
Pantano F, Croset M, Driouch K, Bonnelye E, Iuliani M, Fioramonti M, Santini D, Tonini G & Clezardin PAR (2014) Integrin Alpha5beta1 is a Potential Therapeutic Target to Treat Experimental Breast Cancer Bone Metastasis.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S65-S65)
Pantano F, Croset M, Driouch K, Santini D, Tonini G & Clézardin P (2013) Abstract P5-04-13: Antibody-based therapy targeting integrin a5 is an effective strategy to treat experimental breast cancer bone metastasis. Poster Session Abstracts
Brevet M, Confavreux CB, Pialat J-B, Devouassoux-Shisheboran M, Isaac S, Rousseau J-C, Bringuier P-P, Clezardin P, Thivolet-Bejui F & Girard N (2013) MUTATIONAL PROFILING OF SYNCHRONOUS BONE METASTASES FROM LUNG ADENOCARCINOMA: FEASIBILITY AND RESULTS IN A PROSPECTIVE COHORT OF 46 PATIENTS (POUMOS STUDY). JOURNAL OF THORACIC ONCOLOGY, Vol. 8 (pp S796-S796)
Croset M, Goehrig D, Ansieau S, Puisieux A & Clezardin PAR (2013) Ectopic expression of twist-1 in breast cancer cells promotes bone metastasis formation. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Fradet A, Bellahcene A, Castronovo V, Clezardin PAR & Bonnelye E (2013) Function of ERRa in Mediating Mixed Metastatic Bone Lesion from Prostate Cancer Cells: Implication of Endothelin 1 and Wnt/periostin pathway. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Diaz-Latoud C, Gonin V, Eckel B, Bachelier R, Deux B, Bonnelye E & Clezardin P (2011) Role of axon guidance receptor Robo-1 in training and development of bone metastases of breast cancer. BULLETIN DU CANCER, Vol. 98 (pp S27-S28)
Reynaud C, Pez F, Dayan F, Clezardin P, Sommer P & Pouyssegur J (2011) The HIF-1-inducible Lysyl Oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell. BULLETIN DU CANCER, Vol. 98 (pp S9-S10)
Clezardin P (2011) PATHOPHYSIOLOGY OF TUMORAL BONE DISEASE. OSTEOPOROSIS INTERNATIONAL, Vol. 22 (pp 6-7)
Croset M, Bachelier R, Allioli N, Song S-S, Agami R & Clezardin P (2011) Targeting breast cancer osteomimetic genes by microRNAs-30 decreases the formation of metastatic osteolytic lesions in mice. BULLETIN DU CANCER, Vol. 98 (pp S29-S30)
Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, Touraine J & Clezardin P (2010) Zoledronic acid-induced IPP/Apppl (phosphoantigen) accumulation in human breast cancer cells correlates with Vgamma9Vdelta2 T cell-mediated cancer cell death in vitro and in vivo. BONE, Vol. 47 (pp S266-S267)
Bachelier R, Gonin V, Goehrig D, Deux B, Van der Pluijm G & Clezardin P (2010) The combined targeting of VEGF-A and VEGF receptors inhibits breast cancer bone metastases in mice. BONE, Vol. 47 (pp S322-S323)
Fradet A, Sorel H, Deux B, Clezardin P & Bonnelye E (2010) A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. BONE, Vol. 47 (pp S289-S289)
Gonin V, Bachelier R, Deux B, Contie S, Bonnelye E, Rabbitts P, Wu J & Clezardin P (2010) Involvement of the SLIT2/ROBO1 Pathway in Breast Cancer Bone Metastasis. BONE, Vol. 47 (pp S273-S273)
Lowik CWG, Contie S, Voorzanger-Rousselot N, Litvin J, Clezardin P & Garnero P (2010) Periostin as a circulating marker for breast cancer bone metastases. BONE, Vol. 47 (pp S328-S329)
Stresing V, Deux B, Mathevet P, Ebetino FH & Clezardin P (2010) Frequent intermittent low-dose therapy accentuates the antitumour activity of the bisphosphonate risedronate in vivo. BONE, Vol. 47 (pp S322-S322)
David M, Wannecq E, Jansen S, Deux B, Ribeiro J, Serre C-M, Grès S, Bendriss-Vermare N, Bollen M, Saulnier-Blache J-S , Clézardin P et al (2010) Abstract 2368: Autotaxin/Enpp2 controls of bone metastasis formation through osteoclast function. Tumor Biology
Ricci E, Bourrelly E, Mege LF, Martin X, Clezardin P & Colombel M (2010) 674 EXPRESSION OF INTEGRIN ALPHA 2 AND ALPHA 6 AND C-MET IN PRIMARY PROSTATE CARCONIMA: IMPACT ON BONE METASTASIS FREE SURVIVAL. European Urology Supplements, Vol. 9(2) (pp 221-221)
Voorzanger-Rousselot N, Goehrig D, Clezardin P, Facon T & Garnero P (2008) Platelets Contribute to Circulating Levels of Dickkopf-1 (Dkk-1): Clinical Implications in Multiple Myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 23 (pp S297-S297)
Boucharaba A, Guillet B, Menaa F, Heino M, VanWijnen A, Clezardin P & Peyruchaud O (2008) Lysophospholipids LPA and S1P cooperate to mediate the growth and osteolytic bone metastasis formation of breast cancer. CANCER RESEARCH, Vol. 68(9)
David M, Deux B, Serre CM, Bendriss-Vermare N, Caux C, Saulnier-Blache JS, Clezardin P & Peyruchaud O (2008) Autotaxin controls the metastatic progression of breast cancer cells. BULLETIN DU CANCER, Vol. 95 (pp S91-S92)
Monkkonen H, Benzaid I, Stresing V, Green J, Monkkonen J, Touraine JL & Clezardin P (2008) Zoledronic acid-induced IPP accumulation in cancer cells strongly correlates with gammadelta T-Cell mediated cancer cell death. Bone, Vol. 42 (pp S102-S103)
Bachelier R, Gonin V, Goehrig D, Deux B & Clézardin P (2008) P56. Targeting VEGF and its receptors in the treatment of breast cancer bone metastases. Cancer Treatment Reviews, Vol. 34 (pp 41-41)
Monkkonen H, Benzaid I, Stresing V, Green J, Monkkonen J, Touraine J-L & Clezardin P (2008) P49. Zoledronic acid-induced IPP accumulation in cancer cells strongly correlates with γδ T-cell mediated cancer cell death. Cancer Treatment Reviews, Vol. 34 (pp 37-37)
Clezardin P (2008) New physiopathological pathways of bone metastases. CALCIFIED TISSUE INTERNATIONAL, Vol. 82 (pp S24-S24)
Daubiné F, Fournier P, Ebetino H & Clezardin P (2008) P57. Manipulating the bone mineral affinity of bisphosphonates to directly target cancer cells in the bone marrow. Cancer Treatment Reviews, Vol. 34 (pp 42-42)
David M, Wannecq E, Grès S, Deux B, Serre CM, Bendriss-Vermare N, Caux C, Saulnier-Blache J-S, Clézardin P & Peyruchaud O (2008) P20. Autotaxin promotes metastasis dissemination of breast cancer cells. Cancer Treatment Reviews, Vol. 34 (pp 20-21)
Clezardin P (2008) Cathepsin K inhibitors for treating cancer-induced bone disease. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 25 (pp 15-15)
Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R & Aapro M (2007) 1302 POSTER Updated International Society of Geriatric Oncology (SIOG) recommendations for the use of bisphosphonates in elderly cancer patients with bone metastases. European Journal of Cancer Supplements, Vol. 5(4) (pp 174-174)
Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111)
Boucharaba A, Menaa F, Clezardin P & Peyruchaud O (2007) Role of lysophosphatidic acid (LPA) and LPA1 receptor in the treatment of bone metastases in breast cancer. BULLETIN DU CANCER, Vol. 94(6) (pp 560-561)
Buijs J, Henriquez N, van Overveld P, van der Horsy G, Que I, Schwaninger R, Rentsch C, ten Dijke P, Cleton A, Lidereau R , Bachelier R et al (2007) Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. BONE, Vol. 40(6) (pp S145-S145)
Saltel F, Chabadel A, Zhao Y, Lafage-Proust M, Clezardin P, Jurdic P & Bonnelye E (2006) Transmigration, a new property of mature osteoclasts.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S161-S161)
Peyruchaud O, Boucharaba A, Serre C-M & Clezardin P (2006) The type 1 lysophosphatidic acid receptor (LPA1): identification of a new therapeutic target for patients with bone metastases. CANCER RESEARCH, Vol. 66(8)
Fournier P, Daubiné F, Lundy MW, Ebetino FH & Clézardin P (2006) The direct antitumor activity of bisphosphonates in vivo depends on their bone mineral affinity. Bone, Vol. 38(3) (pp 45-45)
Le Gall C, Guglielmi J, Gasser J, Zimmermann J & Clézardin P (2006) A cathepsin k inhibitor (alone or in combination with zoledronic acid) inhibits the progression of breast cancer bone metastases. Bone, Vol. 38(3) (pp 55-56)
Guglielmi J, Daubiné F, Gasser J, Green J & Clézardin P (2006) Continuous or repeated intermittent low-dose therapy with zoledronic acid induces a sustained inhibition of tumor cell trafficking to bone in vivo. Bone, Vol. 38(3) (pp 44-45)
(2006) Transcriptome analysis reveals an osteomimetic phenotype for human bone metastatic breast cancer cells. CALCIFIED TISSUE INTERNATIONAL, Vol. 78 (pp S85-S86)
(2006) Dickkopf-1 (Dkk-1) is involved in the development of breast cancer osteolytic lesions. CALCIFIED TISSUE INTERNATIONAL, Vol. 78 (pp S27-S27)
Clezardin P & Ctement-Lacroix P (2006) Prevention of breast cancer bone metastasis by an integrin alpha V beta 3 antagonist. CANCER TREATMENT REVIEWS, Vol. 32 (pp S18-S18)
Le Gall C, Gasser J, Bonnelye E, Zimmermann J & Clezardin P (2006) A cathepsin K inhibitor inhibits the progression of breast cancer bone metastases. CANCER TREATMENT REVIEWS, Vol. 32 (pp S16-S16)
Daubine F, Fournier P, Boucher P & Clezardin P (2006) Integrin alpha V beta 3 confers tumor cells a higher sensitivity to the pro-apoptotic effect of the aminobisphosphonate zoledronate in vitro. CANCER TREATMENT REVIEWS, Vol. 32 (pp S45-S46)
Bachelier R, Gonin V, Goehrig D, Confavreux C & Clezardin P (2006) Effects of thrombospondin-1 overexpression and VEGF silencing on bone metastasis formation. CANCER TREATMENT REVIEWS, Vol. 32 (pp S41-S41)
Voorzanger-Rousselot N, Goehrig D, Clezardin P & Garnero P (2006) Serum levels of Dickkopf-1 (Dkk-1) are increased in women with breast cancer and bone metastases. CANCER TREATMENT REVIEWS, Vol. 32 (pp S38-S38)
Boucharaba A, Clezardin P & Peyruchaud O (2006) The type 1 lysophosphatidic acid receptor is a pivotal factor for early and late events for bone metastasis formation in breast cancer. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30)
Fournier PG, Ebetino FH, Castronovo V & Clezardin P (2005) Use of bisphosphonate analogs of risedronate to elucidate antiangiogenic mechanisms of bisphosphonates in vivo. BONE, Vol. 36 (pp S219-S219)
Fournier PG, Ebetino FH, Castronovo V & Clezardin P (2005) Use of bisphosphonate analogs of risedronate to elucidate antiangiogenic mechanisms of bisphosphonates in vivo. CANCER TREATMENT REVIEWS, Vol. 31 (pp S23-S24)
Guglielmi J, Pecheur I, Pujuguet P, Minet D, Baron R, Clement-Lacroix P & Clezardin P (2005) A novel integrin antagonist: Evaluation in bone growth tumor models. CANCER TREATMENT REVIEWS, Vol. 31 (pp S16-S16)
Fournier PGJ, Ebetino FH, Lundy MW & Clezardin P (2005) Use of analogs of risedronate to elucidate antitumor mechanisms of bisphosphonates in vivo. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S37)
Zhao Y, Fournier P, Serre CM, Boucharaba A, Guglielmi J, Peyruchaud O & Clezardin P (2005) Integrin alpha v beta 3 is critical for human breast cancer bone metastasis. CANCER TREATMENT REVIEWS, Vol. 31 (pp S26-S26)
Boucharaba A, Serre C, Blache JS, Bordet J, Clezardin P & Peyruchaud O (2005) LPA: A new local factor acting on breast cancer bone metastasis. CANCER TREATMENT REVIEWS, Vol. 31 (pp S27-S27)
Fournier P, Ebetino FH, Bellahcene A, Castronovo V & Clezardin P (2005) Antibody to rank ligand - Overview of RANK ligand. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P23-P24)
Fournier P, Ebetino FH, Bellahcene A, Castronovo V & Clezardin P (2005) Use of bisphosphonate analogs of risedronate to elucidate antiangiogenic mechanisms of bisphosphonates in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P24-P24)
Zhao Y, Boucharaba A, Fournier P & Clezardin P (2005) Integrin alpha V beta 3 is critical for human breast cancer bone metastasis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P16-P17)
Jackson A, Pujuguet P, Clement-Lacroix P, Baron R, Clezardin P & Garcia T (2005) Genome profiling aiming at identifying "bone metastasis signatures". JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P36-P36)
Bellahcene A, Bachelier R, Detry C, Clezardin P & Castronovo V (2005) Transcriptome analysis reveals an osteomimetic phenotype for human breast cancer cells that selectively target the skeleton. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P32-P32)
Boucharaba A, Serre C, Blache JS, Bordet J, Guglielmi J, Clezardin P & Peyruchaud O (2004) Lysophosphatidic acid: A new link between breast cancer and bone metastasis.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S25-S25)
Guglielmi J, Pecheur I, Pujuguet P, Minet D, Baron R, Clement-Lacroix P & Clezardin P (2004) A nonpeptide integrin avb3 antagonist inhibits bone metastasis formation. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S66-S66)
Fournier PG, Lundy MW, Ebetino RH & Clezardin P (2004) Use of bisphosphonate analogs of risedronate to elucidate antitumor mechanisms of bisphosphonates in vivo.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S25-S25)
Fournier P, Serre CM, Colombel M, Ebetino FH & Clezardin P (2004) The bisphosphonate risedronate inhibits angiogenesis and tumor growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1599-1599)
Clezardin P (2004) Cell adhesion and bone metastasis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1561-1562)
Lundy MW, Ebetino FH & Clezardin P (2004) NE-10790, a phosphonocarboxylate analogue of the bisphosphonate risedronate, exhibits direct antitumor activity in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(6) (pp 1033-1033)
Fournier PG, Lundy MW, Ebetino FH & Clezardin P (2004) NE-10790, A PHOSPHONOCARBOXYLATE ANALOGUE OF THE BISPHOSPHONATE RISEDRONATE, EXHIBITS DIRECT ANTITUMOR ACTIVITY IN IN VIVO. CALCIFIED TISSUE INTERNATIONAL, Vol. 74 (pp S43-S44)
Fournier PG, Lundy MW, Ebetino FH & Clezardin P (2004) NE-10790, a phosphonocarboxylate analogue of the bisphosphonate risedronate, exhibits direct antitumor activity in vivo. BONE, Vol. 34 (pp S56-S57)
Fournier P, Boissier S, Serre C, Colombel M, Ebetino FH & Clezardin PAR (2003) The bisphosphonate risedronate inhibits angiogenesis and tumor growth in vivo.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S113-S113)
Colombel MC, Fournier P, Bouvier R & Clezardin P (2003) Androgens repress the expression of thrombospondin-1, an inhibitor of angiogenesis, in the rat prostate and in hormone-responsive human prostate cancer. JOURNAL OF UROLOGY, Vol. 169(4) (pp 84-84)
Pecheur I, Peyruchaud O, Fournier P, Sarre CM, Bourre F, Delmas PD, Kieffer N & Clezardin P (2002) Integrin alpha v beta 3 plays an essential role in the homing of tumor cells in bone.. BONE, Vol. 30(3) (pp 43S-43S)
Fournier P, Peyruchaud O, Frappart L, Serre CM, Boissier S, Delmas P & Clezardin P (2002) Effects of bisphosphonates zoledronic acid and risedronate on the growth of a human breast carcinoma cell line in vivo. BONE, Vol. 30(3) (pp 40S-40S)
Boissier S, Colombel M, Delmas P, Cabon F & Clezardin P (2002) Zoledronic acid inhibits in vivo experimental angiogenesis. BONE, Vol. 30(3) (pp 38S-38S)
Pecheur L, David M, Schaffer-Reckinger S, Delmas PD, Kieffer N & Clezardin PAR (2000) Ectopic expression of integrin alpha v beta 3 confers tumor cells a high propensity to metastasize to bone.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 15 (pp S177-S177)
Clézardin P (2000) Effects of bisphosphonates on different steps of the metastatic cascade leading to bone metastasis formation. Medecine et Hygiene, Vol. 58(2305 SUPPL.)
Voland C, Kehrel B, Grahe H, Amiral J, Lawler J & Clezardin P (1997) Identification of specific sequences within thrombospondin-1 involved in the formation of irreversible platelet macroaggregates. THROMBOSIS AND HAEMOSTASIS (pp P1385-P1385)
Merle B, Choi HU, Amiral J, Rosenberg L, Lawler J, Delmas PD & Clezardin P (1996) Decorin inhibits cell adhesion by binding to a specific cell adhesive site of thrombospondin.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 11 (pp M460-M460)
Boissier S, Lozano S, Cuzin B, Delmas PD & Clezardin P (1996) Bisphosphonates inhibit tumor cell attachment to unmineralized and mineralized bone extracellular matrices.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 11 (pp P229-P229)
CLEZARDIN P, LOZANO S, LAWLER J, SILVERSTEIN R, LECERF J & DELMAS P (1995) MOLECULAR MECHANISMS OF ATTACHMENT OF CD36-TRANSFECTED CELLS TO THROMBOSPONDIN-1. MOLECULAR BIOLOGY OF THE CELL, Vol. 6 (pp 267-267)
CLEZARDIN P, DROUIN J, KAPLAN C, HANSS M, KEHREL B, SERRE CM, MORELKOPP MC & DELMAS P (1993) MECHANISMS OF PLATELET-OSTEOSARCOMA CELL-INTERACTIONS. THROMBOSIS AND HAEMOSTASIS, Vol. 69(6) (pp 573-573)
CLEZARDIN P, FRAPPART L, CLERGET M, PECHOUX C & DELMAS PD (1993) EXPRESSION OF THROMBOSPONDIN (TSP1) AND ITS RECEPTORS (CD36, CD51) IN NORMAL, HYPERPLASTIC AND NEOPLASTIC HUMAN BREAST. JOURNAL OF CELLULAR BIOCHEMISTRY (pp 159-159)
FRAPPART L, CLEZARDIN P, DANTE R, SERRE CM, CLERGET M & PECHOUX C (1993) ORIGIN AND ROLE OF THROMBOSPONDIN IN THE EARLY DEVELOPMENT OF THE HUMAN MAMMARY-GLAND. JOURNAL OF CELLULAR BIOCHEMISTRY (pp 160-160)
HOTT M, CLEZARDIN P & MARIE PJ (1992) THROMBOSPONDIN INDUCES THE PROLIFERATION OF RAT CALVARIA OSTEOBLASTIC CELLS. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 7 (pp S213-S213)
ABBADIA Z, CLEZARDIN P, SERRE C, MAILLARD C & DELMAS PD (1992) THROMBOSPONDIN MEDIATES PROLIFERATION OF HUMAN OSTEOBLASTIC CELLS INDUCED BY THROMBIN. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 7 (pp S223-S223)
CLEZARDIN P, SERRE CM, TRZECIAK MC, DELMAS P & DROUIN J (1991) THROMBOSPONDIN BINDS TO THE SURFACE OF HUMAN OSTEOSARCOMA CELLS AND MEDIATES PLATELET-OSTEOSARCOMA CELL-INTERACTION. THROMBOSIS AND HAEMOSTASIS, Vol. 65(6) (pp 1055-1055)
DROUIN J, MCLEISH W, SUTHERLAND M & CLEZARDIN P (1991) PSEUDO-GRAY PLATELET SYNDROME - MULTIPLE PLATELET ABNORMALITIES AND NORMAL HEMOSTASIS. THROMBOSIS AND HAEMOSTASIS, Vol. 65(6) (pp 1105-1105)
CLEZARDIN P, ALFARO E, GRANGE J, DESGRANGES C, KAPLAN C, DELMAS P & DECHAVANNE M (1991) THROMBOSPONDIN BINDING BY HUMAN OSTEOSARCOMA CELLS - RELATIONSHIP TO PLATELET-AGGREGATING ACTIVITY OF OSTEOSARCOMA CELLS. PLATELET IMMUNOLOGY : FUNDAMENTAL AND CLINICAL ASPECTS, Vol. 206 (pp 195-207)
CLEZARDIN P, JOUISHOMME H, CHAVASSIEUX P & MARIE PJ (1989) THROMBOSPONDIN AND CELL-ADHESION. THROMBOSIS AND HAEMOSTASIS, Vol. 62(1) (pp 592-592)
CLEZARDIN P, MALAVAL L, DELMAS PD & KAPLAN C (1989) OSTEONECTIN DEFICIENCY IN PLATELETS ISOLATED FROM A PATIENT WITH THE GRAY PLATELET SYNDROME. THROMBOSIS AND HAEMOSTASIS, Vol. 62(1) (pp 420-420)
CLEZARDIN P, MALAVAL L, DELMAS PD & KAPLAN C (1989) A POLYCLONAL ANTIBODY TO OSTEONECTIN INHIBITS COLLAGEN-INDUCED PLATELET-AGGREGATION AND CELL-SURFACE EXPRESSION OF ENDOGENOUS THROMBOSPONDIN. THROMBOSIS AND HAEMOSTASIS, Vol. 62(1) (pp 195-195)
MCGREGOR J, CATIMEL B, PARAMENTIER S, CLEZARDIN P, DECHAVANNE M & LEUNG L (1988) RAPID PURIFICATION AND PARTIAL CHARACTERIZATION OF HUMAN-PLATELET GLYCOPROTEIN IIIB. CLINICAL RESEARCH, Vol. 36(3) (pp A567-A567)
CLEZARDIN P & MCGREGOR JL (1987) STRUCTURAL AND FUNCTIONAL COMPARISON OF THROMBOSPONDIN FROM PLATELETS, ENDOTHELIAL-CELLS AND FIBROBLASTS. THROMBOSIS AND HAEMOSTASIS, Vol. 58(1) (pp 278-278)
Clezardin P & McGregor JL (1987) STRUCTURAL AND FUNCTIONAL COMPARISON OF THROMBOSPONDIN FROM PLATELETS, ENDOTHELIAL CELLS AND FIBROBLASTS. XIth International Congress on Thrombosis and Haemostasis, 6 July 1987 - 10 July 1987.
CLEZARDIN P & DAWES J (1986) STRUCTURAL AND IMMUNOLOGICAL COMPARISON OF THROMBOSPONDIN FROM PLATELETS AND COLOSTRUM. THROMBOSIS RESEARCH (pp 55-55)
BOUKERCHE H, MCGREGOR JL, MCGREGOR L, CLEZARDIN P, DECHAVANNE M, CLEMETSON KJ & BROCHIER J (1985) CHARACTERIZATION OF AN ANTI-THROMBOSPONDIN MURINE MONOCLONAL-ANTIBODY (P8) THAT INHIBITS HUMAN-BLOOD PLATELET FUNCTIONS. THROMBOSIS AND HAEMOSTASIS, Vol. 54(1) (pp 218-218)
ROBERT F, MCGREGOR JL, CLEZARDIN P, SAYEGH A, DECHAVANNE M & CHATAING B (1985) STUDY ON THE RELEASE OF THROMBOSPONDINE DURING PLATELET CONSERVATION - DOSAGE BY MEANS OF THE ELISA METHOD, WITH A MONOCLONAL-ANTIBODY. NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, Vol. 27(2) (pp 117-117)
CLEZARDIN P, MCGREGOR JL, LYON M, BOUKERCHE H, DECHAVANNE M & HUPPERT J (1985) CHARACTERIZATION OF MONOCLONAL-ANTIBODIES WHICH AFFECT HUMAN-PLATELET THROMBOSPONDIN HEMAGGLUTINATION ACTIVITY. THROMBOSIS AND HAEMOSTASIS, Vol. 54(1) (pp 249-249)
MCGREGOR JL, SICARD B, CLEZARDIN P, JAMES E, CLEMETSON KJ & DECHAVANNE M (1984) MEMBRANEOUS PROTEINS AND GLYCOPROTEINS OF ENDOTHELIAL-CELLS FROM UMBILICAL CORDS. NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, Vol. 26(6) (pp 417-417)
CLEZARDIN P, MCGREGOR JL, DECHAVANNE M & CLEMETSON KJ (1983) PLATELET MEMBRANE GLYCOPROTEIN ABNORMALITIES IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS, ACUTE-LEUKEMIA AND SECONDARY THROMBOCYTOSIS. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 218-218)
BENDOUMA M, MCGREGOR JL, CLEZARDIN P, DECHAVANNE M, AGUERCIF M & CLEMETSON KJ (1983) PROTEINS AND GLYCOPROTEINS OF NEONATAL PLATELETS. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 213-213)
CLEZARDIN P, MCGREGOR JL, MANACH M, DECHAVANNE M & CLEMETSON KJ (1983) PURIFICATION OF THROMBOSPONDIN, FIBRONECTIN AND FIBRINOGEN BY FAST PROTEIN LIQUID-CHROMATOGRAPHY. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 16-16)
MCGREGOR JL, CLEZARDIN P, JAMES E, MCGREGOR L, DECHAVANNE M & CLEMETSON KJ (1983) IDENTIFICATION AND CHARACTERIZATION OF FRAGMENTS OF MAJOR MEMBRANE-GLYCOPROTEINS REMAINING ON PLATELETS AFTER CHYMOTRYPSIN TREATMENT. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 187-187)
Clezardin P, McGregor L, McGregor JL, Clemetson KJ & Dechavanne M (1983) Effect of Thrombospondin on Platelet ADP-Induced Aggregation and 125I-Fibrinogen Binding. European Heart Journal, Vol. 4(suppl B) (pp 5-5)
MCGREGOR JL, SICARD B, JAMES E, CLEZARDIN P, DECHAVANNE M & CLEMETSON KJ (1983) MEMBRANE-PROTEINS AND GLYCOPROTEINS OF ENDOTHELIAL-CELLS ISOLATED FROM HUMAN UMBILICAL CORDS. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 396-396)
Clezardin P, McGregor JL, Clemetson KJ, Dechavanne M & Lüscher EF (1981) Further Characterization Of Platelet Membrane Glycoproteins. Oral Presentations, 13 July 1981 - 17 July 1981.
McGregor JL, Clemetson KJ, James E, Clezardin P, Dechavanne M & Lüscher EF (1981) Tryptic Peptide Maps Of The Major Human Blood Platelet Membrane Glycoproteins, Ia, IIa, IIb, IIIa, IIIb and IIIc. Oral Presentations, 13 July 1981 - 17 July 1981.
MCGREGOR JL, CLEMETSON KJ, JAMES E, CAPITANIO A, DECHAVANNE M & LUSCHER EF (1981) ADDITIONAL GLYCOPROTEIN DEFECTS IN GLANZMANN THROMBASTHENIA PLATELETS. THROMBOSIS AND HAEMOSTASIS, Vol. 46(1) (pp 22-22)
CLEZARDIN P, MCGREGOR JL, CLEMETSON KJ, DECHAVANNE M & LUSCHER EF (1981) FURTHER CHARACTERIZATION OF PLATELET MEMBRANE-GLYCOPROTEINS. THROMBOSIS AND HAEMOSTASIS, Vol. 46(1) (pp 108-108)
MCGREGOR JL, CLEMETSON KJ, JAMES E, CLEZARDIN P, DECHAVANNE M & LUSCHER EF (1981) TRYPTIC PEPTIDE MAPS OF THE MAJOR HUMAN-BLOOD PLATELET MEMBRANE-GLYCOPROTEINS, IIA, IIA, IIB, IIIA, IIIB AND IIIC. THROMBOSIS AND HAEMOSTASIS, Vol. 46(1) (pp 22-22)

Preprints

Iamshanova O, Gordienko D, Folcher A, Bokhobza A, Shapovalov G, Mariot P, Allart L, Desruelles E, Spriet C, Diez R , Oullier T et al () Malignant assignment of neuronal Na+ leak channel, NALCN: governor of Ca2+ oscillations-encoded invadopodogenesis, Cold Spring Harbor Laboratory.

Teaching interests

I have supervised a total of 18 PhD students (16 as main supervisor and 2 as co-supervisor) and 9 postdocs.

I am currently module leader of the UE « Metastasis, Migration and EMT » for the Master in Oncology at the University Claude Bernard Lyon-1, Lyon, France.

Professional activities and memberships

I am/was engaged, as academic partner or coordinator, in several research projects/programmes funded by the French National Agency for Cancer (INCa) and INSERM, as well as European projects within the framework of FP6 and FP7, and H2020 research programmes [MetaBre (partner; 2004-2007), PROMET (partner; 2006-2010), BONE-NET (coordinator; 2011-2014), miROMeS (coordinator; 2016-2017)]. In this respect, I received a European Star Award (Paris, France, 2015) as coordinator of the Marie Curie ITN project BONE-NET.

Board of Directors member of the Laboratory of Excellence « DEVweCAN » funded by the French National Research Agency (ANR) (2011-present).

President of the Cancer & Bone Society (CABS; 2009-2010).

Board of Directors member of national and international learned societies (2004-2018) [CABS, International Bone and Mineral Society (IBMS), ARTP (French Prostate Cancer Society), and GEMO ((French Study Group of Bone Metastasis)].

Member of American Association for Cancer Research (AACR), American Society for Bone and Mineral Research (ASBMR), Cancer & Bone Society (CABS), and GEMO.